BRAF基因突变在甲状腺乳头状癌中的临床意义  

Clinical significance of BRAF mutation in papillary thyroid carcinoma

作　　者：赵苏苏 余泽前[2] 李惠 孙怡 王剑蓉 章宜芬 

机构地区：[1]南京中医药大学附属医院江苏省中医院病理科,南京210029 [2]东南大学附属中大医院普通外科,南京210009

出　　处：《临床与病理杂志》2016年第8期1092-1095,共4页Journal of Clinical and Pathological Research

摘　　要：目的:探讨BRAF V600E基因突变与甲状腺乳头状癌的临床相关性。方法:采用PCR技术和直接测序法,对63例甲状腺乳头状癌患者和45例其他类型甲状腺疾病患者石蜡组织BRAF V600E基因突变进行检测。结果:甲状腺乳头状癌组中32例存在突变;而在其他类型甲状腺疾病组中未发现突变。BRAF V600E基因突变在甲状腺乳头状癌不同肿瘤直径组之间的比较差异以及在有无区域淋巴结转移组之间的比较差异均具有统计学意义(P<0.05)。结论:BRAF V600E基因突变与甲状腺乳头状癌的发生、肿瘤的大小和区域淋巴结的转移有关。Objective： To explore the correlation between BARF V600E mutation and papillary thyroid cancer.Methods： hTe BARF V600E mutation status was analyzed in 63 cases of papillary thyroid cancer and 45 cases of other types of thyroid diseases by PCR and direct sequencing technology.Results：32 out of 63 papillary thyroid cancer cases had BARF V600E mutation. However, no mutation was found in tissues from 45 cases of other types of thyroid diseases. BARF V600E mutation was signiifcantly associated with tumor size and regional lymph node metastasis （P〈0.05）.Conclusion： BARF V600E mutation is associated with the pathogenesis, tumor size and regional lymph node metastasis in papillary thyroid cancer.

关 键 词：甲状腺乳头状癌 BRAF 基因突变 

分 类 号：R736.1[医药卫生—肿瘤]